Clinical Trial

A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a phase 1/2, open-label, multicenter study assessing the safety, tolerability, pharmacokinetics and efficacy of GW5282 in participants with locally advanced or metastatic solid tumors. This study comprised of a dose escalation phase to determine the MTD and the RP2D and a dose expansion phase to further explore the safety, PK and efficacy of GW5282.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-26.
Status change: Not Yet Recruiting → Recruiting 2026-02-09
Trial Details
NCT Number NCT07328217
Lead Sponsor Dizal Pharmaceuticals
Conditions Advanced Solid Tumors
Enrollment 203 participants
Start Date 2026-01-29
Primary Completion 2028-12 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-02-11